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Nanotechnology offers a number of nanoscale imple-
ments for medicine. Among these, nanoparticles are 
revolutionizing the field of drug and gene delivery. 
Chitosan is a natural polymer which provides a prof-
itable tool to an innovative delivery system due to its 
inherent physicochemical and biological characteris-
tics. Chitosan nanoparticles are promising drug and 
gene delivery carriers because of small size, better 
stability, low toxicity, inexpensiveness, simplicity, easy 
fabrication and versatile means of administration. 
Chitosan can also be easily modified chemically due to 
the presence of reactive functional hydroxide and 
amine groups. Folic acid is commonly engaged as a 
ligand, for targeting cancer cells, as its receptor, that 
transports folic acid into the cells through endocytosis 
and is over-expressed on the surface of several human 
epithelial cancer cells. Integrating folic acid into  
chitosan-based drug delivery inventions directs the 
systems with a well-organized targeting ability. The 
present review outlines several illustrations of this 
versatile system based on folate decorated chitosan, 
which have shown potential as auspicious delivery sys-
tems published over the past few years. In addition, it 
is probable to formulate chitosan nanocarriers that 
exhibit manifold usage beyond targeted delivery, such 
as nanotheranostics and cancer stem cell therapy. 
 
Keywords: Cancer, chitosan, doxorubicin, drug deliv-
ery, folic acid, 5-fluorouracil, gene delivery. 
 
CANCER is among the foremost causes of morbidity and 
mortality worldwide. According to reports, in 2017, the 
new cancer cases are estimated to about 1,688,780 with 
600,920 cancer deaths in the US1. The therapy utilized 
for treating cancer is chemotherapy. In this technique, the 
fast growing cells are killed using single or a combination 
of drugs. The chemotherapeutic drugs utilized in this  
method are cytotoxic by way of interfering the mitosis or 
cell division of cancer cells. Moreover, chemotherapeutic 
drugs induce stress and initiate apoptosis which results in 
damaging of cells. However, normal cells are also found 
to be susceptible to these effects, in particular cells of 
bone morrow, digestive tract and hair follicles. Recently, 
nanotechnology provided several exciting possibilities in 
destroying cancer cells with minimum damage to the sur-
rounding health tissues. Further, it also helped in the  
detection and elimination of cancer cells before it was 
prone to tumour2,3. A broad variety of substances like po-
lymeric micelles, ligands, lipids and surfactants have 
been used as smart carriers to deliver drugs for cancer 
treatment. To enhance the delivery of drug to the thera-
peutic location by decreasing the delivery of the drug to 
the other sites, polymeric micelles are conjugated with  
ligands for active targeting of tumour cells4. 
 Chitosan is a polysaccharide produced by deacetylation 
of chitin using sodium hydroxide. Chitosan is stable in 
neutral environments and solubilizes in acidic environ-
ments. It can transport a drug to an acidic environment 
and helps in discharging the drug to the preferred site5. 
Chitosan alone exhibits comparatively elongated blood 
circulation time and low uptake by the reticulo endo-
thelial system (RES). Chitosan nanoparticles can target  
tumour sites via the unsystematic and malfunctioning 
vascular architecture in tumour tissue, called the  
enhanced permeability and retention (EPR) effect  
referred to as passive targeting6. EPR is a phenomenon in 
which the molecules of certain sizes are retained in  
tumour tissue more abundantly compared to normal  
tissues. Researchers reported this phenomenon whereby 
tumour cells need to induce the formation of blood ves-
sels for their nutritional and oxygen supply in order to 
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grow faster. This neovasculature usually is not normal and 
is also found to be defective vasculature with poorly  
arranged endothelial cells with wider fenestrations. More-
over, the lymphatic drainage system is absent in tumour  
tissues which makes them putative sites for retention of 
molecules like nanoparticles and other macromolecules7. 
 Folic acid, a ligand, shows more affinity towards its re-
ceptors and hence folic acid and its conjugates exhibit 
advanced drug delivery to cancer cells8. The folated chi-
tosan nanoparticles possess much more cell uptaking abi-
lity than unmodified chitosan, because of folate-mediated 
receptor endocytosis9. Hence, to attain an efficient drug 
delivery through active targeting, chitosan is combined 
with folic acid. The folic acid–chitosan conjugate comes 
together with folate receptors to reach the intercellular 
compartments. The folate receptor and conjugate get de-
tached in an acidic medium and then the receptors revisit 
the cell surface while the folic acid conjugated chitosan 
are degraded by lysosome10. 
 The technologies and systems for transporting a drug in 
the body to accomplish its therapeutic effect for a particu-
lar cancer is known as drug delivery system which can be 
successfully attained through the application of smart car-
riers as shown in Figure 1. The nanoparticles are prospec-
tive candidates as drug delivery vehicles for tumour 
treatment because of their exclusive physicochemical 
characteristics11. Hence, in recent days, researchers con-
centrate more on nanoparticle drug delivery, which en-
ables controlled drug release to specific sites with  
increased bioavailability of drug and eliminates the side-
effects of drugs delivered. This article provides an insight 
on tumour-targeted drug delivery using folate–chitosan 
nanoparticles (FA–CS NPs) for delivering anticancer 
drugs and genes. Information on the physiochemical 
properties of chitosan and folic acid is briefly presented 
below. 
Chitosan 
Chitosan (CS) is a natural, linear carbohydrate polymer 
composed of both acetylated and deacetylated units. This 
cationic polysaccharide is easily obtainable, biocompati-
ble, biodegradable and non-toxic in nature. Chitosan has 
gained increasing attention in therapeutic and biomedical 
applications. It is a deacetylated form of chitin, which is a 
polysaccharide rich in the exoskeleton of shellfish like 
shrimps, lobsters or crabs and cell walls of fungi (Table 
1). Commercially produced CS possesses molecular 
weights ranging between 3800 and 20,000 Da and the 
deacetylation is about 66% to 95%. It is insoluble at neu-
tral pH, but soluble in an acidic surrounding. The solubi-
lity of chitosan in neutral and basic solutions can be 
increased by quaternization12. The molecular weight and 
degree of deacetylation of chitosan affect the physico-
chemical and biological characteristics of chitosan. In 
general, lower molecular weight chitosan with lower degree 
of deacetylation demonstrates superior solubility and more 
rapid degradation than their higher molecular weight 
counterparts13,14. Chitosan, as a type of nanomaterial, carry-
ing anti-tumour drug with noteworthy control-release  
behaviour, has fascinated widespread consideration  
attracting exhaustive studies15. 
Folic acid 
Folic acid is non-immunogenic and economical than  
monoclonal antibodies. It possesses low molecular weight 
with better storage stability and dissolves in water16.  
Folic acid or pteroyl glutamic acid (PGA) consists of p-
aminobenzoic acid connected to the one end of pteridine 
ring and L-glutamic acid at the other end. The folates in 
nature forms can vary in the nature of substituents, reduc-
tion state of the pteroyl group and the number of glutamyl 
groups linked to the pteroyl group. The majority of natu-
rally occurring folates is pteroylpolyglutamates, which is 
 
 
 
 
Figure 1. Schematic representation of nano-based drug delivery. 
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Table 1. Chemical structure and properties of chitosan and folic acid 
Properties Chitosan Folic acid 
 
Molecular formula (C6H11NO4)n C19H19N7O6 
Chemical structure 
 
 
Form Coarse ground flakes and powder Orange to yellow crystalline powder 
Stability Stable Stable 
Water solubility Solubility depends on its molecular weight 1.6 mg/l (25C) 
Storage temperature Room temperature 2–8C 
 
 
attached to the -carboxyl of glutamatein, a form of pep-
tide linkage with two to seven glutamates. Most of the natu-
ral folate gets fond of the polyglutamate chain. The enzyme 
-glutamyl hydrolase present in the small intestine removes 
the polyglumate chain and then the folate is absorbed and 
transported as a monoglutamate into the portal vein17. 
The folic-acid targeted nanoparticles were shown to rec-
ognize cancer cells with high efficiency and show  
reduced toxicity to the non-targeted site. The chemical 
properties of chitosan and folic acid are given in Table 1. 
Chitosan nanoparticle synthesis 
Before venturing into the conjugation of folic acid with 
chitosan nanoparticles, succinct information about the 
synthesis of chitosan nanoparticle is highlighted. Chito-
san NPs can be prepared using numerous methods,  
namely, ionic gelation, polyelectrolyte complex method, 
desolvation, spray-drying and covalent crosslinking, 
which are briefly outlined below. 
Ionic gelation method 
Ionic gelation is the commonly preferred method for pre-
paring chitosan nanoparticles, in which particular concen-
tration of chitosan is liquefied in acetic acid and sodium 
tripolyphosphate is normally used as a linker. Chitosan 
NP is formed by electrostatic interaction between amine 
group of chitosan and negatively charged group of poly-
anion (tripolyphosphate)18. Chitosan nanoparticles can be 
formed by stirring at room temperature. The size of 
nanoparticles can be varied by varying the proportion of 
chitosan and stabilizer. For maximum production of 
nanoparticles, the weight ratio of chitosan : tripolyphos-
phate should be controlled and it was found to be within 
the range of 3 : 1 to 6 : 1 (ref. 19). 
Polyelectrolyte complex method 
Polyelectrolyte complex otherwise, self-assembled poly-
electrolyte, is a term used to define complexes formed by 
charge neutralization and self-assembly of the oppositely 
charged groups, results in hydrophilicity. The size of the 
complexes can be varied from 50 to 700 nm (ref. 20). 
This method deals with simple procedures, avoids the use 
of chemical linkers, thereby decreasing toxicity and other 
unwanted effects of reagents. In these systems, the  
release of drugs may be intensely affected due to charge–
charge interactions. However, these undesirable inter-
actions have been exploited beneficially because of their 
ability to entrap the drug at molecular level for controlled 
drug release21. 
Desolvation method 
It is frequently used technique for chitosan NP synthesis. 
The nanoparticles are synthesized using desolvating 
agents and hence named as desolvation method. Sodium 
sulphate and acetone are the most commonly used pre-
cipitating agents. The desolvating agents can be added 
continuously or intermittently. Chitosan nanoparticles are 
formed by drop wise addition of sodium sulphate into 
chitosan solution. The greater affinity of salt to water  
results in precipitation, inducing desolvation of chitosan 
leading to formation of chitosan nanoparticles22. 
Spray drying method 
Spray drying is the process of making a waterless precipi-
tate from a liquid by rapidly drying with a hot gas. Air is 
used as the drying medium, if the liquid is a combustible 
solvent such as ethanol or an oxygen-sensitive product 
like nitrogen is also used. Spray drying method can be 
used as a one-step preparation of nanoparticle powder, 
and it becomes a noble practice to advance the colloidal 
nanoparticle stability23. 
Covalent cross-linking method 
Chitosan and its derivatives can be synthesized as nano-
particle drug carriers using covalent cross-linking tech-
nique. This method involves the development of covalent 
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bonds between the reactive amino groups of chitosan and 
functional linkers like dicarboxylic acid and glutaralde-
hyde24. 
Chitosan–folic acid conjugation and active  
targeting 
Better therapeutic effects cannot be attained if the thera-
peutic drug is directly conjugated to the targeting ligand 
(FA) because of the reduction in biological activity of 
drug due to conjugation and also because the ligand-
receptor recognition system was disturbed. This limita-
tion can be overcome by polymeric micelles and/or pep-
tide sequences25. The biological activity of the drug can 
be preserved by physically entrapping the drug molecule 
within the nanocarrier (CS). The two carboxyl groups of 
folic acid are named  and . Between these two carboxyl 
groups, the -group shows more reactivity than the -
group in conjugating with the reactive amino group of 
chitosan. The solubility of folic acid in water is improved 
by increasing the temperature or changing the pH, but 
this may disturb the stability of folic acid. Hence di-
methylsulphoxide (DMSO) is used as a solvent for folic 
acid and chosen as a conjugation medium. On the con-
trary, chitosan dissolves in acidic solutions and is insolu-
ble in organic solvents. Hence aqueous buffers or in 
particular combinations with organic solvents miscible 
with water are chosen as a medium for conjugation reac-
tion26. The coupling agents may be used for direct conju-
gation of folic acid to the -COOH group of chitosan. The 
grafting of folic acid to chitosan is also achieved with the 
help of linkers. 2,2-(ethylenedioxy)-bis-(ethylamine) 
(EDBE) has been utilized as a linker between folic acid 
and carboxymethylated27 or succinylated chitosan28. In 
addition to chitosan and chitosan derivatives, it is also 
grafted with copolymers for the delivery of chemothera-
peutic agents and drugs29. 
 A targeted drug delivery system consists of ligand or 
an antibody and can effectively deliver the drug only to 
the targeted site as shown in Figure 2. The effectiveness 
of the drug delivery system depends on physiochemical 
characteristics of the therapeutic agent, ligand and the 
time duration for which the delivery system requests to 
be presented for action30. In some cases the drug is di-
rectly attached to the nano-carrier in which case the 
pharmacological property of therapeutic agent will be 
lost. To avoid this, a ligand is used for active targeting of 
drug delivery. Folic acid, an attractive ligand to folate re-
ceptors, is known to be a potential targeting substance to 
deliver the therapeutic agents through receptor-mediated 
endocytosis because of the overexpression of folate  
receptors in the number of human cancer cells that serve 
as a symbol of tumour, and provide a distinguishable 
marker from normal cells31,32. The effective delivery of 
drugs to the target site can be attained through biological 
interactions like antigen–antibody binding called targeted 
drug delivery. Active targeting utilizes the characteristics  
exhibited by the tumour tissue such as over expression of 
tumour-associated antigens on the surface of the tumour 
tissue33. The interaction between the over-expressing  
antigen on the tumour site and the targeting components 
causes accumulation of drug in the target tissue. As the 
drugs are accumulated only in tumour sites, it decreases 
the side-effects and allows the cellular uptake through  
receptor-mediated endocytosis34 (Figure 3). 
Folic acid conjugated chitosan for the delivery of  
drugs 
There have been many studies on delivery of anti-cancer 
drugs by conjugating highly biocompatible chitosan  
nano-carriers with folic acid. The utilization of folic acid 
as a targeting component can accomplish the targeted  
delivery and enhance the competency of carrier internali-
zation35. Chemotherapeutic drugs can cause side-effects, 
including hair loss, birth defects, ulcer, fatigue and liver 
disease and affect bone marrow function. These side-
effects can be prevented by conjugating the drugs with 
chitosan nanoparticles36. The most commonly used anti-
cancer drugs such as doxorubicin (DOX), 5-fluorouracil 
(5-FU), paclitaxel (PTX) and mitomycin C (MMC) have 
a common problem of solubility, which can be overcome 
by linking with folated chitosan for the targeted delivery 
to cancer cells and these are discussed below. The chemi-
cal structure of the above mentioned poorly soluble anti-
cancer drugs is given in Figure 4. 
Doxorubicin 
DOX is the most universally recommended antitumour 
drug for various types of cancers. It is a weakly soluble 
 
 
 
 
Figure 2. Difference between targeted and normal delivery of drugs. 
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chemotherapeutic agent that produces anticancer mecha-
nisms via suppressing the synthesis of nucleic acid by 
cancer cells. The chitosan nanoparticle was loaded with 
DOX and then conjugated to folic acid for efficient drug 
delivery. The cytotoxic effects were studied through 
MTT assay of doxorubicin loaded folated chitosan 
nanoparticles (DOX-CNPs) using retinoblastoma cells 
(Y-79). The results showed that folated chitosan nanopar-
ticles loaded with DOX possess better cytotoxic effect 
than the unconjugated DOX-CNPs and DOX alone. This 
result was clarified by an improved intracellular uptake  
of DOX-CNPs-FA (30%) compared to DOX-CNPs 
(13.24%) and DOX (5.01%), resulting from the elevated 
attraction of folic acid for folate receptors37. The chitosan 
nanoparticles were loaded with both doxorubicin and pyr-
rolidinedithiocarbamate (PDTC) with more significant  
 
 
 
 
Figure 3. Folic acid–chitosan mediated endocytosis of drugs in can-
cer cells. 
 
 
 
 
 
 
Figure 4. Chemical structure of anticancer drugs. 
scientific inference against liver cancers. The encapsulating 
ing efficiency of DOX and PDTC was about 77.64% and 
86.54% respectively. DOX-loaded nanoparticles demon-
strated a lower IC50 signifying that FA-CS nanocarriers 
enhanced cell uptake efficiency, which was also demon-
strated by fluorescence microscopy38. The anticancer acti-
vity of folate-linked carboxymethyl chitosan (CMCS)-
iron (II, III) oxide (Fe3O4)-doped cadmium telluride 
(CdTe) quantum dot (QDs) nanoparticles (CFLMNPs) 
was studied in normal L02 and HepG2 cancer human 
hepatocytes. The outcome of this research indicates that 
the carrier possesses high drug loading capacity and the 
drug was taken up by the cell through the mechanism of 
folate receptor mediated endocytosis39. Hu et al.40 indus-
trialized a drug delivery system via conjugating the folate 
with trimethylchitosan (FTMC)/graphene oxide (GO) 
nanocomplexes (FGNCs) for the targeted delivery of 
DOX to the tumour cells. An insignificant cytotoxicity of 
FGNCs was observed in HeLa and A549 cells. The 
higher uptake level in HeLa cells with folate–receptor 
demonstrated the targeting capability of FGNCs. The  
efficiency of targeting delivery might decline the toxicity 
of the loaded anticancer therapeutic agent40. DOX was 
incorporated into the biodegradable succinyl chitosan 
nanoparticles functionalized with folic acid which were 
explained to be non-toxic in vitro. The nanoparticles 
showed excellent loading capacity for doxorubicin and 
reported a pH-dependent drug release28. The folic acid 
linked cholesterol-modified glycol chitosan (FCHGC) 
micelles were produced and employed for the targeted 
drug delivery of DOX to the cancer cells. The results of 
the study demonstrated that cytotoxicity was significantly 
increased against FR-positive HeLa cells than the free 
DOX41. The pH-dependent drug releasing mechanism 
was studied by Chen et al.42. To attain targeted drug de-
livery of DOX, smart pH-dependent polymeric micelles 
were developed. The pH-responsive micelles depended 
on deoxycholic acid and folic acid co-modified hydro-
xypropyl chitosan of various substitutions. The results 
specified that pH-responsiveness of DOX-release behav-
iour was heavily reliant on the attached proportions of 
two hydrophobic components. The DOX-release behav-
iour was due to the gradual hydrolysis of amide bond and 
electrostatic repulsion between the protonated DOX and 
the amino residue of the Chitosan backbone under a  
tumourous environment42. Folate-conjugated Chitosan 
was used as a shell material to coat the pluronic F127 for 
delivery of DOX to cancer cells. The drug release pattern 
of shell structured system was slow and sustained than 
the uncoated polymeric micelle delivery system. It was 
suggested that this controlled drug release was succeeded 
by dissemination of drug via polymer wall and enzymatic 
degradation of chitosan. Cell viability was not disturbed 
by nanoparticles at concentrations lesser than 1 mg/ml 
(ref. 43). Folate-conjugated chitosan was loaded with 
other polymers or inorganic materials like graphene oxide 
REVIEW ARTICLES 
 
CURRENT SCIENCE, VOL. 113, NO. 8, 25 OCTOBER 2017 1535 
(GO), carbon nanotube (CNT) with the anticancer drug 
doxorubicin (DOX) through – staking. These inorganic 
nanosheets are soluble in water and polar solvents and it 
potentially enables the drug delivery system with great 
drug loading capability and controlled drug release. The 
research demonstrated a slow drug release at physiologi-
cal pH (~11% after 72 h) and an increased release at low 
pH, particularly in the first 24 h (~35%)44,45. Folate–
receptor targeted nanoparticles using chitosan–folic acid 
and dextran succinate-doxorubicin (ChitoFA and DexSU-
DOX) conjugates were fabricated and studied using KB 
cells. The results revealed that folic acid-dextran (FA-
Dex) nanoparticles effectively suppressed tumour growth 
by folate receptor targeting. These results suggested that 
DOX-loaded FADex nanoparticles are potential carriers 
for anticancer drug delivery46. The folate-grafted chitosan 
nanoparticles showed greater efficiency in cell uptake, 
approximately twice that of the non-folate grafted chito-
san nanoparticles. The IC50 of DOX-loaded NPs were  
almost 10-fold lesser than that of free DOX. The results 
on the other hand, found no noteworthy change between 
cytotoxicity profiles of DOX-loaded CS and FA-CSNPs, 
as recommended by IC50 of DOX-loaded CSNPs and FA-
CSNPs containing DOX of 34 and 26 g/ml respectively. 
Folated chitosan is also used to coat single-walled carbon 
nanotubes for the targeting system. This targeting system 
demonstrated no significant toxicity compared to free 
DOX and showed more stability under physiological 
conditions along with effective release of DOX. The tar-
geting system exhibited cytotoxicity to the hepatocellular 
carcinoma cell line (SMMC-7721) and suppressed the 
growth of liver cancer in nude mice47. 
5-Fluorouracil 
Fluorouracil (5-FU) is a medication that has been  
employed in innumerable tumour treatments for more 
than 20 years, and is still deliberated as an active anti-
neoplastic drug in advanced colorectal cancer and malig-
nancies of the head and neck. The specific cell targeting 
of PLGA-1,3-diaminopropanefolic acid and its nanoparti-
cles loaded with 5-FU for HT-29 cells was boosted by  
increasing the conjugating ratio of folic acid. The conju-
gation ratio of 46.7% was attained by means of 1,3-
diaminopropane as a cross-linker. The non-motility of  
folic acid into PLGA-based drug carriers due to 1,3-
diaminopropane, revealed that the formulation can be 
very well employed as a specific drug delivery system for 
cancer cells48. Manganese-doped zinc sulphide quantum 
dots were engaged to track the path of 5-fluorouracil  
encapsulated in folate carboxymethylchitosan (CMC) 
nanoparticles. The breast cancer cell line MCF-7 was 
employed to study the specific targeting and cytotoxicity 
of the drug loaded nanoparticles, while another cell line, 
L929 was used to prove non-toxicity to non-cancerous 
tissue. Nanoparticles established cytotoxicity to MCF-7 
cells and were non-toxic to mouse fibroblast L929 cells. 
Additionally, nanoparticles exhibited a specific attachment 
to the MCF-7 cells expressing folate receptors; at the 
same time, non-folate conjugated nanoparticles exhibited 
no specific cell attachment49. The drug encapsulation ef-
ficiency (EE) of 5-FU-NPs was explored by LC–MSMS 
(liquid chromatography–mass spectroscopy mass spec-
troscopy) and it was found to be 29.3%. These experi-
ments revealed that 5-FU loaded chitosan nanoparticles 
can be propelled as smart drug delivery mediators for 
cancer treatments50. The inorganic multifunctional nano 
vehicle -zirconium phosphate@folate acid–chitosan–
rhodamine6G (5-FU/Fe3O4/-ZrP@CHI-FA-R6G) for 
cancer treatment was successfully fabricated and directed 
towards the cancer cell. The cancer cells were recognized 
by folic acid through its biological affinity. Cell culture 
studies revealed the ability of drug-release system as an 
operational twin nano-carrier for the delivery of anticancer 
drug into cancer cells. Drug release in vitro on the  
attained nanocomposites displayed a sustained drug release 
profile51. Folic acid conjugated to carboxymethyl chito-
san (CMCS) using PEG was employed in the targeted de-
livery of 5-FU to the cancer cells. The potential ability 
and cytotoxicity of (CMCS-5-FU)-PEG-FU were investi-
gated in HeLa and A549 cells. The MTT assay results 
suggest that the cytotoxicity of the proposed drug carrier 
system was higher than the non-folate CMCS-5-FU 
which in turn revealed that the cellular uptake efficiency 
of 5-FU loaded CMCS-PEG-FA was affected by folate–
receptor-mediated endocytosis. The solubility of CMCS-
PEG-FA at physiological pH, targeting efficiency and its 
potential in carrying anticancer drugs makes it a promis-
ing candidate for the targeted delivery of chemotherapeu-
tic agents52. Targeted folate receptor modified with 
chitosan as the carrier material for 5-fluorouracil was  
fabricated. In vitro drug release investigation indicated 
chitosan drug-loaded microspheres showed good slow re-
lease effect with 70% and 40% release rate after 24 h in 
simulation of gastric and intestinal juice respectively, 
which revealed that the drug release rate was relevant to 
medium pH value53. The folated poly[(p-nitrophenyl 
acrylate)-co-(N-isopropylacrylamide)] submicrogels (F-
SubMGs) was prepared and used as a delivery system of 
anticancer drug 5-FU. The cytotoxicity of unloaded and 
5-FU loaded F-SubMGs was studied in MCF7 and HeLA 
cells. The results showed that the cytotoxicity of  
unloaded F-SubMGs was low, compared with FU loaded 
F-SubMGs; however toxicity increased with increase in 
F-SubMGs concentration. As the HeLa cells are folate  
receptor-positive, the cellular uptake efficiency of  
F-SubMGs was higher in HeLa cells than MCF7 cells. 
These results demonstrate that the mean residence time of 
the drug was increased to 60 days and, therefore, the 
folate-conjugate submicrogels have great efficiency in 
controlling the release of 5-FU, which may lead to an in-
novative choice for treating numerous malignancies54. 
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Paclitaxel 
Paclitaxel (PTX) is a hydrophobic antitumour drug used 
to treat different kinds of tumour with notable anticancer 
activity. Nano carriers which can enrich PTX solubility, 
advance PTX pharmacokinetic profiles in vivo, reduce its 
side-effects, passively or actively target tumour sites  
because of EPR effect55. The active targeting system to 
tumour cells, folate linked stearic acid grafted chitosan 
oligosaccharide (Fa-CSOSA) was fabricated by You et 
al.56 A549 and HeLa cells were used to study the target-
ing efficiency of Fa-CSOSA micelles. The results showed 
that Fa-CSOSA micelles exhibited higher expression of 
folate receptors in less than 6 h. Further, for Taxol (a 
clinical formulation containing PTX) the obtained values 
of IC50 on A549 and HeLa cells were found to be 7.0 and 
11.0 g ml−1 respectively. Moreover, the cytotoxicity of 
PTX-loaded micelles was enhanced abruptly, indicating 
improved intracellular delivery of the drug56. PTX-loaded 
folate-conjugated chitosan (FA-CTS/PTX) was fabricated 
and its in vitro cytotoxicity against HeLa cells was exam-
ined. The PTX-loaded FA-CTS nanoparticles exhibited 
potent cytotoxicity against HeLa cells, an effect 2- to 3-
fold stronger than that of PTX-loaded CTS nanoparti-
cles57. The grafting of folic acid to N-octyl-N-phthalyl-
3,6-O-(2-hydroxypropyl) chitosan (OPHPC) resulted in 
an average molecular weight of 70 kDa. The PTX micelle 
formulation amplified its apparent solubility by 4000-fold 
than the free PTX. The cellular uptake studies empha-
sized that a considerably greater quantity of PTX accu-
mulated in a human breast adenocarcinoma cell line 
(MCF-7) compared with free Taxol®58. Deoxycholic  
acid-O-carboxy methylated chitosan conjugated with  
folic acid and formulated PTX loaded micelles was syn-
thesized. The micelles were of spherical shape, sized 
<200 nm, and had a negative zeta potential (–21 mV) that 
increased its uptake by the liver, spleen and lung.  
Particles were synthesized to prolong blood circulation 
and consequently change the bio-distribution of PTX than 
Taxol® injection. The drug loading efficiency and encap-
sulation efficiency were found to be 26.5% and 90.3%, 
respectively. An increased localization of PTX in the 
spleen, lung and liver, and diminished accumulation in 
the heart and kidney were observed. The micelles were 
more effective in delivering PTX to the spleen, lung, and 
liver in comparison with Taxol® injection. Additionally, 
they decreased the distribution of drug in heart and kid-
ney, enabling a reduction of PTX adverse side-effects in 
clinical practice, particularly regarding cardiotoxicity and 
renal toxicity59. PTX-loaded FA–CH–PLA nanoparticles 
possess an encapsulation efficiency of 90% and release 
PTX in a controlled manner. The uptake of PTX loaded 
FA–CH–PLA nanoparticles was found to be 11 g/ml 
which was greater than 6-fold improving capabilities 
compared to the free PTX. PTX-loaded FA–CH–PLA  
nanoparticles had more than three-fold enhancing capaci-
ties to prompt MCF-7 cell apoptosis than free PTX60. The 
stearic acid grafted carboxymethyl chitosan (molecular 
weight of 230  40 kDa and degree of deacetylation (DD) 
85%) was modified with folic acid to form amphiphilic 
nanoparticles possessing pH-sensitive dissolution (pH 
5.6), low cytotoxicity and high amount of drug encapsu-
lation. PTX-loaded nanoparticles (5–25 g/ml) exhibited 
a noteworthy viability inhibiting effect on tumour cells 
(HeLa) over-expressing FR in comparison to non-over-
expressing NIH/3T3 cells, with IC50 values of PTX 
loaded nanoparticles of 10.5 and 25 g/ml respectively61. 
Mitomycin C  
Mitomycin C (MMC) is a chemotherapeutic mediator and 
utilized as a therapy for esophageal carcinoma, breast, 
anal and bladder cancers. But it causes numerous side-
effects such as nausea, vomiting, hair loss, skin rash, lung 
damage and shortness of breath when administered as a 
free drug. Hence it is conjugated with chitosan to treat 
cancer with reduced side-effects. The chitosan nanoparti-
cles were modified with mPEG and folate to selectively 
deliver the anticancer drug MMC to cancer cells. The use 
of both PEG and folic acid led to enhanced nanoparticle 
uptake by tumour cells and the blood circulation time was 
increased. The in vitro study demonstrated a biphasic  
behaviour with a slower release after an initial burst  
release. In vivo studies of chitosan nanoparticles modified 
with both mPEG and folate, coated with MMC, were car-
ried out on 4-week-old mice. The nanoparticles were im-
planted subcutaneously with hepatoma-22 cells of a 
mouse. Bio-distribution was studied using rhodamine B-
labeled particles when tumours reached 0.2–0.5 cm in  
diameter. Both folated nano-carriers (FA-NPs and mPEG-
FA-NPs) displayed higher level of tumour tissue accumu-
lation than the non-folated (mPEG-NPs) carrier system62. 
PEG-modified chitosan nanoparticles (CS-NPs) were 
loaded with both mitomycin C and methotrexate (MTX) 
as a multi-drug delivery system in which folic acid acts 
as a targeting ligand. In vitro cell viability analysis speci-
fied that the (MTX + MMC)–PEG–CS–NPs presented a 
concentration- and time-dependent cytotoxicity. Further-
more, in vitro cellular uptake recommended that 
(MTX + MMC)–PEG–CS–NPs could be proficiently  
taken up by cancer cells via FA receptor-mediated endo-
cytosis. In contrast, (MTX + MMC)–PEG–CS–NPs can  
co-deliver MTX and MMC to not only attain the highest 
accumulation at tumour site but also powerfully reduce 
the growth of tumour cells compared with the delivery of 
a single drug63. The derivatives of N-succinyl-chitosan 
were loaded with MMC and the conjugate is soluble in 
water when the MMC content is less than 12%, due to the 
hydrophilic property of N-succinyl-chitosan. These con-
jugates possessed excellent anti-cancer activity against a 
number of cancers such as murine leukemias (L1210 and 
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P388), and a murine hepatic cell carcinoma (MH134)64. 
The folate functionalized MMC-SPC (soybean phos-
phatidyhlcholine) phospholipid complexes when loaded 
with 10-hydroxycamptothecin (HCPT), possessed nano 
size, well-regulated drug loading efficiency, and pH-
dependent drug release. The in vitro study revealed that 
MMC/HCPT loaded FA micelles presented an increased 
uptake by tumour cells through receptor-mediated endo-
cytosis. The result of in vitro cell viability study pre-
sented that the MMC/HCPT loaded FA-micelles 
demonstrated time- and concentration-dependent cytotox-
icity. The cytotoxicity of combined drugs is significantly 
enhanced compared to both the free drugs and necessarily 
deters tumour growth than free drugs65 as represented in 
Figure 5. MMC–SPC complex loaded phytosomes 
(MMC-loaded phytosomes) as drug carriers were surface-
modified with folate-PEG (FAPEG) to attain reduced tox-
icity and a superior MMC mediated therapeutic effect. 
The outstanding properties of FA-PEG-MMC-loaded 
phytosomes comprise better cellular uptake in HeLa cells 
and developed accumulation in H22 tumour-bearing mice 
over that of the PEG-MMC-loaded phytosomes. More-
over, FA-PEG-MMC-loaded phytosomes were accompa-
nied with superior cytotoxic activity in vitro and an 
enhanced antitumour effect in vivo compared to that re-
sulting from free MMC injection66. 
Folic acid conjugated chitosan for the delivery of  
genes 
The usage of chitosan and its derivatives as gene trans-
porters displays good biocompatibility and biodegradabi-
lity, but the low transfection efficiency of DNA and low 
cell specificity, should be upgraded before testing in 
clinical trials. Folic acid modified chitosan is one of the 
most universally engaged carriers for specific cell target-
ing not only for drug delivery but also for gene delivery. 
These systems possibly encourage internalization of nucleic 
acids into the cell through receptor-mediated endocytosis 
with the overall result of improving the transfection  
 
 
 
 
Figure 5. Multi-drug delivery utilizing folic acid-chitosan drug deliv-
ery system. 
efficiency. The synergism of formulation of folic acid-g-
chitosan/DNA complexes as nanoparticulates and target-
ing ability can lead to significant advancements in gene 
delivery67. In a study, the FA and PEG were linked to  
chitosan-graft-polyethylenimine (CHI-g-PEI) to improve 
solubility and transfection efficiency. The FA-PEG-
grafted CHI-g-PEI (FA-PEG-CHI-g-PEI) successfully 
decomposed the plasmid DNA (pDNA) into nanoparticles 
with a positive surface charge under an appropriate nitro-
gen/phosphorus (N/P) ratio. The transfection efficiency 
of FA-PEG-CHI-g-PEI/pDNA complex in 293T cells and 
LoVo cells, which are the folate receptors-over express-
ing cell lines, increased with increasing N/P proportion, 
but there was no noteworthy change in human lung  
carcinoma cells (A549), which are the folate receptors-
deficient cell lines. The copolymer presented less cyto-
toxicity and showed high FA-media receptor specificity 
in vitro than the 25 kDa PEI and CHI-g-PEI. FA–PEG–
CHI-g-PEI displayed enhanced transfection efficiency  
in vivo that represents the ability of FA–PEG–CHI-g-PEI 
to be a harmless as well as an effective gene carrier68.  
Folated poly(ethylene glycol)-chitosan-graft-polyethylen-
imine (FPCP) was fabricated and characterized. The  
results proposed that FPCP has low cytotoxicity in differ-
ent cells, and FPCP–DNA complexes exhibited better 
specificity and increased transfection efficiency. Addi-
tionally, FPCP complexes reduced tumour growth more 
efficiently than PEI in H-ras12V liver cancer mice. From 
the observed results, it is evident that enhanced transfec-
tion efficiency and specific cell targeting is beneficial in 
gene therapy for liver cancer69. The physicochemical cha-
racteristics of folated-PEG and dual amino acid-modified 
chitosan (CM–PFA) complexed with DNA were evaluated 
by FTIR. The CM–PFA nanocarriers presented better 
biocompatibility and were internalized by target cells,  
attaining a 3.7 times rise in gene expression. In vivo-
mimicking 2D co-cultures established a genuine attrac-
tion to tumour cells and an insignificant uptake in non-
cancerous cells70. Nanoparticles containing an Au–Ag 
bimetallic core and a folated-chitosan shell (Au–Ag@CS-
FA) NPs were consequently premeditated by numerous 
techniques such as scanning electron microscopy (SEM), 
Fourier transform infrared spectroscopy (FTIR), trans-
mission electron microscopy (TEM) and UV-visible spec-
tra. DNA binding capability was also assessed. The 
results indicate that Au-Ag@CS-FA NPs are stable with 
better biocompatibility and strong DNA binding capacity 
that make them outstanding transportater of genes71.  
A chitosan-poly(ethylenimine) linked with folic acid 
(CP1.3K-FA) possesses reduced cytotoxicity with enhan-
ced transfection efficiency. CP1.3K-FA demonstrated 
higher transfection ability than the unmodified chitosan-
poly(ethylenimine) copolymer and it was comparable 
with the transfection efficiency of Fugene HD in B16 and 
U87 cells, which suggests that CP1.3K-FA can be used as a 
gene carrier for cancer treatment72. Yan et al.73 synthesized 
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Table 2. Overview of cancer drug delivery using folic acid–chitosan conjugation 
Drug Type of cancer Key findings Reference 
 
Doxorubicin (DOX) Retinoblastoma  Better cytotoxic effect 34 
  Improved intracellular uptake 
 Liver cancer Enhanced the cell uptake 35 
 Liver cancer High drug loading capacity 36 
  Folate receptor mediated endocytosis 
 Lung cancer Higher cell uptake 37 
 Cervical cancer Excellent loading capacity 38 
  pH dependent drug release 
 Liver cancer Increased cytotoxicity 25 
 Lung cancer pH dependent and closely related with the  39 
    grafting proportions of two hydrophobic  
    ingredients 
 Breast cancer Controlled drug release  40 
  More effective folate-mediated endocytosis 
 Oral cancer Effective suppression of tumour growth 43 
 Liver cancer Efficient cell uptake 44 
  More stable 
 
5-Fluorouracil (5-FU) Colon cancer Improved specific cell targeting  45 
 Breast cancer Non-toxicity to non-cancerous tissue 46 
 Cervical cancer Sustained drug release profile 47 
 Lung cancer Increased solubility of drug 49 
  Enhanced targeting efficiency 
 Breast cancer Increased cytotoxicity 51 
  Increased mean residence time of drug 
 
Paclitaxel (PTX) Lung cancer Higher expression of folate receptor 53 
  Enhanced cytotoxicity  
  Improved intracellular delivery  
 Cervical cancer Improved cytotoxicity 54 
 Breast cancer Enhanced solubility and cellular uptake 55 
 Breast cancer Increased apoptosis induction 57 
  Controlled drug release  
 Cervical cancer pH dependent 58 
  Improved drug encapsulation efficiency  
 
Mitomycin C (MMC) Liver cancer Enhanced cellular uptake 59 
  Increased blood circulation time  
  Higher level of tumour tissue accumulation  
 Cervical cancer Concentration and time dependent cytotoxicity 60 
  Powerfully suppress the growth of tumour cells  
 Cervical cancer Well-controllable drug loading efficiency 62 
  Sustained and pH-dependent drug release  
 Liver cancer Better cellular uptake 63 
  Superior cytotoxicity  
  Enhanced antitumour effect  
 
 
a new kind of Tat tagged and folate-modified N-succinyl-
chitosan (Tat–Suc–FA) nanoparticles, for delivery of 
genes to cancer cells. The Tat–Suc–FA NPs exhibited 
less toxicity than chitosan displayed by cytotoxicity as-
say. The particle size of Tat–Suc–FA/DNA complexes 
exhibited a spherical and compact morphology and was 
found to be in the range of 54 and 106 nm. Zeta poten-
tials of these complexes varied from 3 to 44 mV as the 
weight ratio changed. Overall, the results propose that 
low toxic Tat–Suc–FA cationic polymers could be con-
sidered for gene delivery vectors73. The designed folic 
acid modified with Schiff-base conjugated imidazolechi-
tosan (FA–SLICS) having pH sensitive Schiff-base moie-
ties along chitosan backbones resulted in controlled and 
targeted release of loaded pDNA in the endosomal micro-
environment. FA–SLICS has insignificant cytotoxicity to 
non-cancerous cells, but presents slight toxicity to cancer 
cells (HeLa and HepG2)74. Further, for effective folate 
receptor-expressing ovarian cancer cells transfection, the 
siRNA/folic acid–poly(ethylene glycol)–chitosan oligo-
saccharide lactate (FA–PEG–COL) nanoparticles were 
fabricated. FA–PEG–COL nanoparticles exhibited greater 
blood compatibility and enhanced cell viability than COL 
nanoparticles. In vitro transfection and gene knockdown 
efficiency of HIF-1 were found to be superior than COL 
nanoparticles in the range of 76%–62%. Further, active
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Figure 6. Application of nanotheranostics for active targeting of cancer stem cells. 
 
Table 3. Outline of gene delivery using folic acid–chitosan conjugation 
Nanocarrier  Findings Reference 
 
FA–PEG–CHI–g-PEI Increased transfection efficiency in folate receptor positive cells  65 
  (293T cells and LoVo cells) 
 No noteworthy changes in folate receptors deficient cell lines (A549) 
 
FPCP Low cytotoxicity 66 
 Good cancer cell specificity  
 Increased transfection efficiency  
 
CM–PFA Better biocompatibility 67 
 Enhanced gene expression  
 Insignificant uptake in normal cells  
 
Au–Ag@CS–FA Strong DNA binding ability 68 
 Stable with good biocompatibility  
 
CP1.3K–FA Reduced cytotoxicity 69 
 Enhanced transfection efficiency  
 
Tat–Suc–FA Less toxicity 70 
 Efficient condensation of DNA  
 
FA–SLICS Controlled and targeted delivery 71 
 Insignificant cytotoxicity to normal cells  
 Efficiently transfect folate receptor positive cells  
 
FA–PEG–COL Greater compatibility with erythrocytes 72 
 Superior gene knockdown efficiency  
 
FA–LA–PMLA–LMC Highlighted the importance of hydrophobic and hydrophilic  73 
   grafting degrees 
 
FPCPHDs Enhanced gene transfection and expression in KB cells 74 
 
F–PEG–g-TMC and mPEG–g-TMC Improved cellular uptake 75 
 Increased transfection efficiency  
 
 
targeting FA–PEG–COL nanoparticles indicated higher 
accumulation than passive targeting COL nanoparticles75. 
FA modified amphiphilic linoleic acid (LA) and poly (-
malic acid) (PMLA) double-grafted chitosan (LMC) 
nanoparticles (NPs) were prepared for the co-delivery of 
PTX and surviving shRNA-expressing plasmid (iSur-
pDNA). PTX loading, cellular uptake, nuclear accumula-
tion of pDNA, in vitro gene silencing efficiency, and cell 
growth inhibition were stimulated through FA function-
alization and greater grafting degree of LA, but inhibited 
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by increasing grafting degree of PMLA. In tumour-bearing 
mice, co-delivery of PTX and iSur-pDNA presented  
superior antitumour activity and extended survival pe-
riod76. A pH-dependent core-shell system FA-PEG-CCTS/ 
PAMAM/HMGB1/pDNA nanocomplexes (FPCPHDs), 
was synthesized and examined. FPCPHDs exhibited neg-
ligible toxic effects on HepG2 and KB cells and im-
proved gene transfection and expression in KB cells 
displayed by luciferase activity assay and RFP fluores-
cence intensity analysis. In addition, gene transfection 
and expression in KB cells were subdued by free folic 
acid77. Folate-poly(ethylene glycol)-grafted-trimethyl chi-
tosan (F-PEG-g-TMC) and methoxypolyethylene glycol-
grafted-trimethyl chitosan (mPEG-g-TMC)/pDNA com-
plexes were fabricated and tested. The cellular uptake of 
F-PEG-g-TMC/pDNA with N/P ratio of 20 in KB cells 
was amplified by 1.68 times than that of mPEG-g-
TMC/pDNA (N/P ratio 20) resulting in 1.5-fold and 1.4-
fold improved transfection efficiency in KB cells and 
SKOV3 cells respectively. F-PEG-g-TMC/pDNA showed 
increased cellular uptake and transfection efficiency when 
compared with folate-TMC/pDNA because of the stabi-
lizing effect of PEGylation78. 
Conclusion 
In this review, the application of smart carriers based on 
folated chitosan was reported. Among the chitosan nano-
particle synthesis techniques discussed, the most widely 
developed are ionic gelation and polyelectrolyte complex 
methods as these possess an advantage of easy synthesis 
of chitosan nanoparticle without the use of organic sol-
vents and harmful conditions. Several studies have 
pointed out the possible application of folated chitosan 
nanoparticles for tumour-specific delivery of antitumour 
agents and a number of illustrations presenting promising 
results are summarized in Tables 2 and 3. At present, the 
chitosan-based gene carrier is efficient in folate receptor 
positive cells like ovarian, breast, colon, renal, lung, etc. 
and increases transfection efficiency with low cytotoxi-
city79, when compared with non-folate receptor cells. 
Hence, the codelivery of drug and gene to non-folate re-
ceptor cancer cells should be better exploited for superior 
anticancer activity. 
 An attention-grabbing aspect underlined by the de-
scribed systems beyond targeted delivery can be related 
to the concept of nanotheranostics80. Nanotheranostics, a 
clever practice targets to observe the consequence of 
treatment given, enhances drug efficacy and safeguarding 
the patient. A comprehensive study on nanotheranostic 
techniques for cancer should be encountered to assist in 
personalizing chemotherapy. Cancer stem cells are not 
responsive to chemotherapy and subsequently incline to 
persist in the body even after a course of treatment was 
completed, and they can repeatedly prompt cancer recur-
rence or metastasis as displayed in Figure 6. The folated 
chitosan nanoparticles to deliver an anti-tumour drug, 
which kills both cancer cells and cancer stem cells con-
siderably diminish cancer recurrence are to be fabricated 
and investigated in depth with more pre-clinical trials. 
Additional improvements are required to turn the concept 
of targeting both cancer cells and cancer stem cells based 
on folated chitosan nanoparticle technology into a realis-
tic practical application as the next generation of drug  
delivery system. 
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